A delicate balancing act for Immunogen

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, May 21, 2019 at 9:42 AM.

  1. #1 cafead, May 21, 2019 at 9:42 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,979
    Likes Received:
    3
    via Expect Immunogen to have had a busy weekend: for one, it will likely have been working the phones with its bankers after last week’s wounding setback for its lead asset, mirvetuximab. But discussions should also have turned to how Jazz Pharmaceuticals might be persuaded to opt in to two early assets, IMGN779 and IMGN632.

    article source
     
    Quote

Reply to Thread